Risk Sleuth
GMED · 10-K filed 24 Feb 2026 · year to 31 Dec 2025

Globus Medical

38 named things its latest annual report says its results depend on, each in the company's own words. 24 of them are also named by other companies we've read.

Read the filing on SEC.gov ↗

Customers

Group purchasing organizations

earns fromnamed as a risk
This in turn has resulted and will likely continue to result in greater pricing pressures and the exclusion of certain suppliers from important market segments as group purchasing organizations, independent delivery networks and large single accounts continue to use their market power to consolidate purchasing decisions for hospitals.Risk factors (Item 1A)

Also named by BAX, BDX, BSX, CDW, EW, GWW, SYY, USFD and 1 more

Suppliers

Allograft tissue banks

depends on · Less than five third-party suppliersnamed as a risk
Less than five third-party suppliers currently supply all of our needs for allograft implants and products, other than those implants and products that we process ourselves.Risk factors (Item 1A)

Third-party component suppliers

depends onnamed as a risk
Because of the nature of our internal quality control requirements, regulatory requirements and the custom and proprietary nature of components, we cannot quickly engage additional or replacement suppliers for many of our critical components.Risk factors (Item 1A)

Partners and platforms

Independent distributors

depends onnamed as a risk
Some of our independent distributors account for a significant portion of our sales volume, and if any such independent distributor were to cease to distribute our products, our sales could be adversely affected.Risk factors (Item 1A)

Also named by FLO, GRC, IR

Other companies

Nevro Corp.

$5.85 per sharenamed as a risk
The success of the NuVasive and Nevro Mergers will depend on, among other things, our ability to realize the anticipated synergies, efficiencies and other benefits from combining the businesses of Globus and NuVasive and Nevro, respectively.Risk factors (Item 1A)

NuVasive, Inc.

named as a risk
There can be no assurances that the NuVasive and Nevro businesses can be integrated successfully.Risk factors (Item 1A)

Competitors

Medtronic

competes withnamed as a risk
We believe that our significant competitors are Medtronic, DePuy Synthes, Stryker, Zimmer Biomet, Smith + Nephew and VB Spine.Risk factors (Item 1A)

Also named by DXCM

Smith + Nephew

competes withnamed as a risk
We believe that our significant competitors are Medtronic, DePuy Synthes, Stryker, Zimmer Biomet, Smith + Nephew and VB Spine.Risk factors (Item 1A)

Also named by SOLV

DePuy Synthes

competes withnamed as a risk
We believe that our significant competitors are Medtronic, DePuy Synthes, Stryker, Zimmer Biomet, Smith + Nephew and VB Spine.Risk factors (Item 1A)

Stryker

competes withnamed as a risk
We believe that our significant competitors are Medtronic, DePuy Synthes, Stryker, Zimmer Biomet, Smith + Nephew and VB Spine.Risk factors (Item 1A)

Zimmer Biomet

competes withnamed as a risk
We believe that our significant competitors are Medtronic, DePuy Synthes, Stryker, Zimmer Biomet, Smith + Nephew and VB Spine.Risk factors (Item 1A)

VB Spine

competes withnamed as a risk
We believe that our significant competitors are Medtronic, DePuy Synthes, Stryker, Zimmer Biomet, Smith + Nephew and VB Spine.Risk factors (Item 1A)

Physician-owned distributorships (PODs)

competes withnamed as a risk
The proliferation of PODs could result in increased pricing pressure on our products or harm our ability to sell our products to physicians who own or are affiliated with those distributorships.Risk factors (Item 1A)

Places

International markets (outside U.S.)

earns from · approximately 19.4% of our total salesnamed as a risk
During the year ended December 31, 2025, international sales accounted for approximately 19.4% of our total sales.Business (Item 1)

Also named by ABNB, ADSK, BSX, CROX, CRWD, DOCU, DXCM, EFX and 18 more

United Kingdom

earns fromnamed as a risk
A significant portion of our foreign revenues and expenses are generated in Japan, the Euro zone, UK and Australia.Risk factors (Item 1A)

Also named by AGX, AJG, AMP, BAC, BF/B, BGC, BRO, C and 59 more

Brazil

operates innamed as a risk
Specifically, we have operations in Puerto Rico, Brazil, and Argentina, each of which have markets subject to financial instability or currency controls.Market risk (Item 7A)

Also named by ADM, ASO, AZO, BALL, CPAY, CPRT, CTVA, DE and 32 more

Japan

earns fromnamed as a risk
A significant portion of our foreign revenues and expenses are generated in Japan, the Euro zone, UK and Australia.Risk factors (Item 1A)

Also named by A, AAPL, AFL, AMKR, ANET, BMY, BSX, CAT and 25 more

Australia

earns fromnamed as a risk
A significant portion of our foreign revenues and expenses are generated in Japan, the Euro zone, UK and Australia.Risk factors (Item 1A)

Also named by AJG, ARWR, AXP, BF/B, BTU, CL, CSGP, CVX and 15 more

Argentina

operates innamed as a risk
Specifically, we have operations in Puerto Rico, Brazil, and Argentina, each of which have markets subject to financial instability or currency controls.Market risk (Item 7A)

Also named by BALL, C, ECL, FISV, INGR, JNJ, KMB, MDLZ and 6 more

Puerto Rico

operates innamed as a risk
Specifically, we have operations in Puerto Rico, Brazil, and Argentina, each of which have markets subject to financial instability or currency controls.Market risk (Item 7A)

Also named by AMGN, BMY, BPOP, CCI, COO, HPE, LLY, PWR and 2 more

Euro zone

earns fromnamed as a risk
A significant portion of our foreign revenues and expenses are generated in Japan, the Euro zone, UK and Australia.Risk factors (Item 1A)

United States

earns from
The primary market for our products is the United States (“U.S.”), where we sell our products through a combination of direct sales representatives employed by us and sales representatives employed by our exclusive independent distributors, who distribute our products on our behalf for a commission that is generally based on a percentage of sales.Business (Item 1)

Also named by ABBV, ADP, AJG, AMGN, APA, AXGN, AXP, BALL and 139 more

Pennsylvania

operates in
Our implant products are manufactured in our facilities in Eagleville, Pennsylvania, Limerick, Pennsylvania and West Carrollton, Ohio.Business (Item 1)

Also named by AWK, CNX, DTM, EQT, FE, NFG, PEG, PPL and 6 more

Costa Rica

operates in
Through the Nevro Merger our spinal cord simulation products such as the HFX™ SCS platform including the Senza® SCS, are manufactured in our Costa Rica facility.Business (Item 1)

Also named by COO, EW

San Antonio, Texas

operates in
Most of our regenerative biologic products are processed in our facilities in San Antonio, Texas, and in Audubon, Pennsylvania.Business (Item 1)

Also named by RHP

Methuen, Massachusetts

operates in
The Excelsius® robotic systems are assembled in our facility in Methuen, Massachusetts.Business (Item 1)

Commodities and inputs

Human tissue (allograft)

depends onnamed as a risk
In addition, due to seasonal changes in mortality rates, some scarce tissues used in our regenerative biologics products are at times in particularly short supply.Risk factors (Item 1A)

Regulators

U.S. Food and Drug Administration (FDA)

subject tonamed as a risk
On July 16, 2024, Globus Medical, Inc. received a warning letter from the FDA following an inspection of our facilities in Audubon, Pennsylvania.Business (Item 1)

Also named by A, ABBV, ABT, AMGN, ARE, ARWR, ATR, AXGN and 112 more

Centers for Medicare and Medicaid Services (CMS)

subject tonamed as a risk
As the portion of the U.S. population over the age of 65 and eligible for Medicare continues to grow, we may be more vulnerable to coverage and reimbursement limitations imposed by CMS.Business (Item 1)

Also named by ABBV, CDNA, CHE, DGX, DOC, ENSG, GD, GEHC and 6 more

Medicines and Healthcare products Regulatory Agency (MHRA)

subject tonamed as a risk
Complying with this new regulatory framework will require us to invest in additional resources and could be expensive, time-consuming and disruptive to our existing operations in the UK.Business (Item 1)

Also named by EW, HIMS, LH

Laws and programs

U.S. tariffs

exposed to its price · universal baseline tariff of 10%named as a risk
Specifically, changes to tariffs and trade policies have and could continue to impact the cost of raw materials and components necessary for our operations, disrupt our global supply chain and create additional operational challenges.Risk factors (Item 1A)

Also named by A, AAPL, ACHR, ADI, AEHR, AEP, AIOT, AKAM and 170 more

Medicare

earns fromnamed as a risk
Maintaining and growing sales of our products depends on the availability of adequate coverage and reimbursement from third-party payors, including government programs such as Medicare and Medicaid, private insurance plans and managed care programs.Risk factors (Item 1A)

Also named by ABT, ARWR, AXGN, BAX, BDX, BMY, BSX, CAH and 48 more

Medicaid

earns fromnamed as a risk
Medicaid payments to physicians and facilities are often lower than payments by other third-party payors and some state Medicaid programs may not pay an adequate amount for the procedures performed with our products, if any payment is made at all.Risk factors (Item 1A)

Also named by ABBV, ABT, ARE, ARWR, BAX, BMY, BSX, CHE and 39 more

Stark Law

subject tonamed as a risk
We would be materially and adversely affected if regulatory agencies interpret our financial relationships with surgeons who order our products to be in violation of applicable laws and we were unable to comply with applicable laws.Risk factors (Item 1A)

Also named by CHE, DVA, HCA, LH, RMD

No Surprises Act

subject tonamed as a risk
These measures could limit the amount we can charge and recover for the IONM services we furnish where we have not contracted with the patient’s insurer, which could negatively impact the profitability of our IONM services business.Risk factors (Item 1A)

Also named by ELV, HCA, MOH, OSCR

EU Medical Device Regulation 2017/745 (MDR)

subject tonamed as a risk
All medical device companies intending to manufacture and/or market products in the EEA (including Globus), will be required to comply with requirements of the MDR, which increased technical documentation requirements, imparted more labeling obligations of higher risk devices, and altered the classification of some of our products.Business (Item 1)

Also named by ECL, KVUE

Technology

ExcelsiusGPS robotic system

named as a risk
The letter describes observed non-conformities in establishing and maintaining product complaint procedures, including complaint investigations, risk reconciliation, and Medical Device Report procedures including timely reporting, pertaining to the ExcelsiusGPS® robotic system.Business (Item 1)

Senza SCS system

subject to
The Senza SCS system is a Class III device subject to review and approval through the PMA pathway.Business (Item 1)